Eli Lilly (LLY +0.1%) CEO John Lechleiter tells NYT in a lengthy profile that "we're trying to...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Eli Lilly (LLY +0.1%) CEO John Lechleiter tells NYT in a lengthy profile that "we're trying to be realistic while maintaining our optimism," but the drug maker is losing patent protection in the next seven years on drugs that accounted for 74% of its sales in 2009, a decline considered to be the worst patent cliff facing major companies in the industry.